FO
SIOX

FT Options’s Sio Gene Therapies Inc. Common Stock SIOX Stock Holding History

FT Options’s Portfolio SIOX Stock Details SIOX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$514K Buy
9,334
+8,108
+661% +$1.37M 0.77% 44
2017
Q2 		$227K Buy
+1,226
New +$215K 0.39% 55

Other funds holding SIOX

QF
QVT Financial New York $1.37B AUM 148.1% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PC
PointState Capital New York $7.9B AUM 42.31% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
IA
IPL Advisers New York $158M AUM 18.16% 1-Year Est. Return
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

FT Options's SIOX Position: Q3 2017 in Review

FT Options increased its Sio Gene Therapies Inc. Common Stock (SIOX) stake by 661% in Q3 2017, buying an estimated $1.37M and bringing the position to 9,334 shares worth $514K. The position accounts for 0.77% of the portfolio, ranked #44.

FT Options first reported a position in SIOX in Q2 2017 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold SIOX as of Q3 2017.

  • FT Options held 9,334 shares of Sio Gene Therapies Inc. Common Stock worth $514K as of Q3 2017.
  • FT Options bought 8,108 Sio Gene Therapies Inc. Common Stock shares in Q3 2017, an estimated $1.37M.
  • Sio Gene Therapies Inc. Common Stock made up 0.77% of FT Options's portfolio in Q3 2017, its #44 holding.
  • FT Options first reported a position in Sio Gene Therapies Inc. Common Stock in Q2 2017 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Sio Gene Therapies Inc. Common Stock as of Q3 2017.

Based on FT Options's 13F filing for Q3 2017, filed 13 Nov 2017.